The American Spectator

home
ADVERTISEMENT
Print Email
Text Size

The Spectacle Blog

At least, don't think about ordering the latest pharmaceuticals.  The London authorities like to save money.  That means not paying much for drugs.  Which means that British patients aren't likely to get them.

Reports the Guardian:

Life-saving medicines meant only for sale in the UK are being sold for export at huge mark-ups, causing an acute shortage of drugs that is putting patients' lives at risk, the Observer has established.

A "shopping list" from would-be buyers sent to UK pharmacies and wholesalers and seen by the Observer reveals they are being encouraged to sell on some medicines for up to 30% more than they would get from the NHS.

Pharmacies are being offered £930 for a course of Humira, a medicine for rheumatoid arthritis that they normally buy for £715, giving them an instant profit of 30%. Those involved in the trade - believed to be a handful of rogue pharmacies and wholesalers - are offering £76.50 for a month's course of Femara, a drug used to treat breast cancer patients, which UK pharmacies can buy for £60.85, earning them a 25% profit.

A pre-filled syringe of Aranesp, used to treat chronic renal failure, can be sold on for a 21% mark-up. The burgeoning trade can be attributed to the slide in the value of sterling against the euro, which has meant UK drug prices are now some of the cheapest in Europe.

But no worries about ObamaCare.  Once the Clinton administration takes over health care payments and benefits, everything will be wonderful.  More people will be covered for more procedures, spending will fall, and the deficit will be reduced.  And North Korea will disarm, the Iranian mullahs will convert to Christianity, Israel and the Palestinians will make peace, and the lion will lie down with the lamb.

Don't worry, be happy.

View all comments (5) | Leave a comment

martin j smith| 3.8.10 @ 7:24AM

I have about as much faith in the British Government in our current one. ZERO. In anything.

A Balrog of Morgoth| 3.8.10 @ 10:28AM

"Pharmacies are being offered £930 for a course of Humira, a medicine for rheumatoid arthritis that they normally buy for £715, giving them an instant profit of 30%."

Maybe I am being obtuse, but don't most businesses sell goods for more than it costs to buy them? Is a 30% markup all that unusual, or is it a bit on the LOW end of the spectrum? And, of course, there is no mention of overhead costs.

TomSwift| 3.8.10 @ 12:18PM

The average profit of a firm is 8%, although in medicine it's 20% since regulation works to keep out competition. However, these profits are for researching new medicines, curing people, etc. The profits mentioned are for bypassing government price controls.

PCC| 3.8.10 @ 3:51PM

I just saw a pig fly past my window.

Bob| 3.8.10 @ 5:47PM

Americans wanted change. They did not care what kind of change, they did not care if that change meant the destruction of our way of life, destruction of our freedoms, destruction of every advancement in our society. Americans voted for change and if that meant playing Russian Roulette a fully loaded revolver, that is a OK. Just put the muzzle to your head and pull the trigger, and Americans will get the change they voted for!

Leave a Comment

N.B. We encourage readers to share and discuss their thoughtful and relevant comments about this Spectator article. Comments are routinely monitored and will be deleted if profane, bigoted, or grossly impolite. Please be respectful. (And don't feed the trolls!) Thank you.

More Blog Posts by Doug Bandow

http://spectator.org/blog/2010/03/08/dont-get-sick-in-great-britain

ADVERTISEMENT

SPONSORED LINKS

Special Feature

Better that we become a nation of choosers rather than beggars. Our symposium on choice from the May, 2012 issue:

A Time for Choosing

James Piereson

The Road from Serfdom

Stephen Moore and Peter Ferrara

FLASHBACK TO: 1984

Clip of the Day

Most Popular Articles

Meet the Flukes!

F. H. Buckley | 5.25.12

The Wisconsin Turning Point

Peter Ferrara | 5.23.12

In Search of Muhammad

Aymenn Jawad Al-Tamimi | 5.25.12

Age and Kyl

Quin Hillyer | 5.25.12

Follow Me

Jay D. Homnick | 5.25.12

A Test of National Honor

Hal G.P. Colebatch | 5.25.12

How About the Record of DOE Capital?

William Tucker | 5.25.12

The Great Debate

R. Emmett Tyrrell, Jr. | 5.24.12

ADVERTISEMENT